Endometrial endometrioid adenocarcinoma
MONDO:0006192A primary endometrial adenocarcinoma composed of neoplastic cells that form complex glandular patterns associated with budding and branching of the neoplastic glands. The neoplastic glands resemble those of the normal endometrium and may or may not be associated with sheet-like proliferation of malignant cells. Endometrioid adenocarcinoma is the most commonly seen morphologic variant of endometrial adenocarcinoma.
Also known as: endometrial endometrioid adenocarcinoma, endometrioid adenocarcinoma of endometrium, endometrioid adenocarcinoma of the endometrium, endometrioid carcinoma of endometrium, endometrioid carcinoma of the endometrium, endometrioid endomet. adenocar., endometrioid endometrial adenocarcinoma, uterine corpus endometrioid adenocarcinoma
2902 clinical trials for this condition and its sub-types, 56 tagged with Endometrial endometrioid adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrial endometrioid adenocarcinoma
-
Could a hormonal IUD replace surgery for some uterine cancers?
Disease control OngoingThis study looks at whether a hormonal intrauterine device (IUD) alone or combined with the drug everolimus can treat precancerous changes or very early-stage endometrial cancer. About 100 women with these conditions will receive the IUD, and some will also take everolimus if the…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New study tackles obesity in endometrial cancer survivors
Disease control OngoingThis study helps early-stage endometrial cancer survivors with obesity start a weight management program and possibly take weight loss medications. Researchers want to see if referring patients to a weight loss clinic helps them begin treatment. The goal is to improve long-term h…
Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced (stage III or IV) or recurrent endometrial cancer. About 800 participants received either the combo or chemo alone. The …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat uterine cancer
Disease control OngoingThis study tests a combination of two drugs, alpelisib and fulvestrant, in people with a specific type of advanced uterine cancer (endometrioid endometrial cancer) that has a PIK3CA gene mutation. The goal is to see if the treatment can shrink or control the cancer. About 51 part…
Phase 2 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a daily pill keep BRCA-Linked ovarian cancer at bay?
Disease control OngoingThis Phase 3 trial is investigating whether the drug olaparib can help women with a specific type of ovarian cancer stay in remission longer. The study includes women whose cancer has returned but responded well to platinum-based chemotherapy, and who carry a BRCA gene mutation. …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) works better than hormone therapy alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer will receive either…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Virus therapy targets Hard-to-Treat endometrial cancer
Disease control OngoingThis early-stage trial tests a specially modified virus (VSV-hIFNbeta-NIS) given through an IV to people with advanced or recurrent endometrial cancer. The virus is designed to attack cancer cells while leaving healthy cells alone, and it includes a tracer to see where it goes in…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug combo aims to outsmart Chemo-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immunotherapy plus radiation may keep endometrial cancer from returning
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard radiation therapy can better prevent cancer recurrence in people with newly diagnosed, early-stage endometrial cancer that has a specific genetic feature (mismatch repair deficiency). About 164 parti…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for recurrent ovarian and endometrial cancers? drug tazemetostat under study
Disease control OngoingThis phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase II trial tests whether adding ribociclib to a standard two-drug regimen (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. About 90 participants will be randomly assigned to receive either the two-drug or three-drug combin…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug duo aims to halt hard-to-treat endometrial cancer
Disease control OngoingThis early-phase study tests whether combining two drugs, DKN-01 and pembrolizumab, can help control advanced or recurrent endometrial cancer that cannot be cured with surgery or radiation. Eight adult women with this type of cancer will receive the combination. The main goals ar…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug duo aims to halt endometrial cancer growth
Disease control OngoingThis study tests a combination of two drugs, abemaciclib and letrozole, in people with advanced or recurrent endometrioid endometrial cancer that cannot be cured by surgery or radiation. The main goal is to see how many participants have no cancer growth after 6 months of treatme…
Phase 2 • Sponsor: Gynecologic Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingThis phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New scan and dye combo may spot hidden cancer in lymph nodes
Diagnosis OngoingThis study looks at whether combining a special scan (PET/CT) with a dye that highlights lymph nodes can better detect cancer spread in women with high-risk endometrial cancer. About 100 women scheduled for surgery will get both tests before their operation. The goal is to see if…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to predict cancer return in Low-Risk patients
Knowledge-focused OngoingThis study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifyi…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can emotional distress shape Ovarian-Sparing surgery choices?
Knowledge-focused OngoingThis study looks at how psychological distress and reproductive concerns affect young women's decisions about whether to keep their ovaries during surgery for early-stage endometrial cancer. Researchers will also examine whether women feel regret about their choice after the oper…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Virtual therapy trial for cancer fear pulled before starting
Knowledge-focused CancelledThis trial was designed to test whether an online mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer returning or getting worse. The study planned to compare the online program to standard educational materials. Howev…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC